A Next-Generation, Targeted-Action Probiotic
CLB101™ is the world’s first and only commercially available Anaerostipes caccae probiotic for functional formulations—delivering a novel, next-generation solution. As a strict anaerobe and direct butyrate-producer, CLB101™ advances gut health by optimizing intestinal barrier function, restoring microbial balance, and supporting immune health.*
Benefits of Anaerostipes caccae CLB101™:
High Butyrate Production
Restores a keystone strain that resides naturally in the colon and produces butyrate, an essential short-chain fatty acid for colonic health*
Strengthens Intestinal Barrier
Strengthens and reduces gut barrier permeability, which is crucial for overall gut health*
Maintains Microbial Balance
Promotes a healthy gut microbiome by creating a low-oxygen environment for beneficial bacteria to grow*
Calms Gut Inflammation
Stimulates the growth of specialized immune cells that keep inflammation in check*
Why Choose CLB101™?
Of consumers say they’re optimizing or healing their guts.
As featured in NutraIngredients USA
ClostraBio self-affirms GRAS status for next-gen probiotic CLB101™
Chicago-based ClostraBio, Inc. has announced that an independent expert panel has confirmed the self-affirmed Generally Recognized as Safe (GRAS) status of its Anaerostipes caccae CLB101™ probiotic strain. The designation, along with its NDI-exempt status, clears the way for introduction of CLB101™ into the U.S. market as the first and only commercially available strain of Anaerostipes caccae.
Want to innovate with us?
We work with brand innovators, formulators and contract manufacturers.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.